![]() Nebulization of nanocrystals: production of respirable solid-in-liquid-in-air colloidal dispersion. Nanoparticle technology for drug delivery-from nanoparticles to cutting-edge delivery strategies. Physicochemical characterization of a new respirable form of nedocromil. Pulmonary delivery of deslorelin: large porous PLGA particles and HPβCD complexes. Large porous particles for pulmonary drug delivery. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Recent advances in pulmonary drug delivery using large, porous inhaled particles. Therapeutic significance of distal airway inflammation in asthma. Regional lung deposition and bronchodilator response as a function of β 2-agonist particle size. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, 2002. Guidance for industry: nasal spray and inhalation solution, suspension, and spray drug products-chemistry, manufacturing, and controls documentation. Drug 19:425–498 (2002).Ĭenter for Drug Evaluation and Research (CDER). Pulmonary drug delivery systems: recent developments and prospects. Comparison of particle sizing techniques in the case of inhalation dry powders. Aerodynamics and aerosol particle deaggregation phenomena in model oral–pharyngeal cavities. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. Aerosolisation behaviour of micronised and supercritically-processed powders. ![]() Shekunov (eds.), Supercritical Fluid Technology for Drug Product Development. Production of powders for respiratory drug delivery. Characterization of submicron systems via optical methods. Fundamental effects of particle morphology on lung delivery: predictions of Stokes’ law and the particular relevance to dry powder inhaler formulation and development. Micrometer-scale particle sizing by laser diffraction: critical impact of the imaginary component of refractive index. Particle size analysis: AAPS workshop report, cosponsored by the Food and Drug Administration and the United States Pharmacopoeia. Proceedings of the Conference on Respiratory Drug Delivery, Boca Raton, FL, X:287–295 (2006).ĭ. Inspired by design: evaluating novel particle production techniques. For illustration purposes, special consideration is given to the analysis of aerosols using time-of-flight and cascade impactor measurements, which is supported by a computational analysis conducted for this review. This review offers an in-depth discussion on particle size analysis pertaining to specific pharmaceutical applications and regulatory aspects, fundamental principles and terminology, instrumentation types, data presentation and interpretation, in-line and process analytical technology. Thus, to enable selection of the most appropriate or optimal sizing technique, cross-correlation between different techniques may be required. The fundamental issue with particle size analysis is the variety of equivalent particle diameters generated by different methods, which is largely ascribable to the particle shape and particle dispersion mechanism involved. Physicochemical and biopharmaceutical properties of drug substances and dosage forms can be highly affected by the particle size, a critical process parameter in pharmaceutical production.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |